Inhibitory effects of ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal odels

Journal of Agricultural and Food Chemistry

Volumn 57, Issue 11, 2009, Pages 5049-5057

  Weng, Chia Jui ^a,b   Chau, Chi Fai ^a   Yen, Gow Chin ^a   Liao, Jiunn Wang ^a   Chen, Deng Hai ^c   Chen, Kuang Dee ^c  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAINAN UNIVERSITY OF TECHNOLOGY   (Taiwan)

^c Double Crane Group   (Taiwan)

Author keywords

Ganoderma lucidum; Invasion; Lucidenic acid; Metastasis; MMP 9 activity

Indexed keywords

ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ANIMAL; ARTICLE; CANCER INVASION; CHEMISTRY; GANODERMA LUCIDUM; GENE EXPRESSION REGULATION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLANT EXTRACTS; REISHI;

ANIMALIA; BASIDIOMYCOTA; GANODERMA LUCIDUM; MUS;

EID: 67149099452     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf900828k     Document Type: Article

References (33)

1. Teow, S. S. The effective application of Ganoderma nutriceuticals. In Recent Progress in Ganodenna lucidum Research; Kim, B. K., Moon, C. K., Kim, T. S., Eds.; Pharmaceutical Society of Korea: Seoul, South Korea, 1997; pp 21-39.
2. Song, Y. S.; Kim, S. H.; Sa, J. H.; Jin, C.; Lim, C. H.; Park, E. H. Antiangiogenic and inhibitory activity on inducible nitric oxide production of the mushroom Ganoderma lucidum. J. Ethnophamacol. 2004, 90, 17-20.
3. Wang, A.C.; Li, B. Ganoderma; Beijing Science and Technology Press: Beijing, China, 2002 (in Chinese).
4. Weiss, L. Metastatic inefficiency. Adv. Cancer Res. 1990, 54, 159-211.
5. Condeelis, J.; Segall, J. E. Intravital imaging of cell movement in tumours. Nat. Rev. Cancer 2003, 3, 921-930.
6. Scorilas, A.; Karameris, A.; Arnogiannaki, N.; Ardavanis, A.; Bassi-lopoulos, P.; Trangas, T.; Talieri, M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 2001, 84, 1488-1496.
7. Arii, S.; Mise, M.; Harada, T.; Furutani, M.; Ishigami, S.; Niwano, M.; Mizumoto, M.; Fukumoto, M.; Imamura, M. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996, 24, 316-322.
8. Sakamoto, Y.; Mafune, K.; Mori, M.; Shiraishi, T.; Imamura, H.; Mori, M.; Takayama, T.; Makuuchi, M. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int. J. Oncol. 2000, 17, 237-243.
9. Weng, C. J.; Chau, C. F.; Chen, K. D.; Chen, D. H.; Yen, G. C. The anti-invasive effects of lucidenic acids isolated from a new Ganoderma lucidum strain. Mol. Nutr. Food Res. 2007, 51, 1472-1477.
10. Chu, S. C.; Chiou, H. L.; Chen, P. N.; Yang, S. F.; Hsieh, Y. S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinog. 2004, 40, 143-149.
11. Okuda, K. Hepatocellular carcinoma: dinicopathological aspects. J. Gaslroenterol. Hepatol. 1997, 12, 314-318.
12. Cheng, J. C.; Chou, C. H.; Kuo, M. L.; Hsieh, C. Y. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-κB signal transduction pathway. Onogene 2006, 25, 7009-7018.
13. Sugita, K. Recent advances in inhibitors of metalloproteinases for cancer therapy. IDrugs 1999, 2, 327-339.
14. Wojtowicz-Praga, S. Clinical potential of matrix metalloproteinase inhibitors. Drugs Res. Dev. 1999, 1, 117-129.
15. 30 triterpenoids form the fungus Ganoderma lucidum (Reishi). J. Agric. Food Chem. 1985, 49, 1793-1798.
16. Wu, T. S.; Shi, L. S.; Kuo, S. C. Cytotoxicity of Ganoderma lucidum triterpenes. J. Nat. Prod. 2001, 64, 1121-1122.
17. Weng, C. J.; Chau, C. F.; Hsieh, Y. S.; Yang, S. F.; Yen, G. C. Lucidenic acid inhibit PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-κB and AP-1. Carcinogenesis 2008, 29, 147-156.
18. Chen, D. H.; Shiou, W. Y.; Wang, K. C.; Huang, S. Y.; Shie, Y. T.; Tsai, C. M.; Shie, J. F.; Chen, K. D. Chemotaxonomy of triterpenoid pattern of HPLC of Ganoderma lucidum and Ganoderma tsugae. J. Chin. Chem. Soc. 1999, 46, 47-51.
19. Chen, D. H.; Chen, K. D. Determination of ganoderic acids in triterpenoid constituents of Ganoderma tsugae. J. Food Drug Anal. 2003, 11, 195-200.
20. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
21. Nzeako, U. C.; Goodman, Z. D.; Ishak, K. G. Comparison of tumor pathology with duration of survival of north American patients with hepatocellular carcinoma. Cancer 1995, 76, 579-588.
22. Ishak, K. G.; Goodman, Z. D.; Stocker, J. T. Tumors of the Liver and Imrahepatic Bile Ducts; Armed Forces Institute of Pathology: Washington, DC, 2001.
23. Liu, Y. W.; Gao, J. L.; Guan, J.; Qian, Z.M.; Feng, K.; Li, S. P. Evaluation of antiproliferative activities and action mechanisms of extracts from two species of Ganoderma on tumor cell lines. J. Agric. Food Chem. 2009, 57, 3087-3093.
24. Liu, F.; Qi, H. L.; Chen, H. L. Regulation of differentiation- and proliferation-inducers on Lewis antigens, α-fucosyltransferase, and metastatic potential in hepatocarcinoma cells. Br. J. Cancer 2001, 84, 1556-1563.
25. Masure, S.; Billiau, A.; Van Damme, J.; Opdenakker, G. Human hepatoma cells produce an 85-kDa gelatinase regulated by phorbol-12-myristate-13-acetate. Biochem. Biophys. Acta 1990, 1054, 317-325.
26. Sato, H.; Seiki, M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8, 395-405.
27. Takahra, T.; Smart, D. E.; Oakley, F.; Mann, D. A. Induction of myofibroblast MMP-9 transcription in three-dimensional collagen I gel cultures: regulation by NF-κB, AP-1 and Spl. Int. J. Biochem. Cell Biol. 2004, 36, 353-363.
28. Folkman, J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995, 333, 1757-1763.
29. Lochter, A.; Bissell, M. J. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999, 107, 128-136.
30. Stetler-Stevenson, W. G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 1999, 103, 1237-1241.
31. MacDougall, J.R.; Matrisian, L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 1995, 14, 351-362.
32. Kolin, E. C.; Liotta, L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995, 55, 1856-1862.
33. Tonn, J. C.; Kerkau, S.; Hanke, A.; Bouterfa, H.; Mueller, J. G.; Wagner, S.; Vince, G. H.; Roosen, K. Effect of synthetic matrix metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int. J. Cancer 1999, 80, 764-772.